Overview

Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To investigate and compare the drug amount delivered to the body after each single administration of Rotigotine patch with 2 different formulations in healthy Japanese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
UCB Pharma
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
N 0437
Rotigotine